
Erratum

Erratum to: Tumor Static Concentration Curves in Combination Therapy

Tim Cardilin,^{1,2,8} Joachim Almquist,^{1,3} Mats Jirstand,¹ Alexandre Soselly,^{4,5} Christiane Amendt,⁶
Samer El Bawab,⁴ and Johan Gabrielsson⁷

Published online 5 January 2017

Erratum to: AAPS J

DOI: 10.1208/s12248-016-9991-1

Equation 6: The complete system should read

$$\begin{aligned}\frac{dV_1}{dt} &= I(C_{\text{cetuximab}})k_g V_1 - S(C_{\text{cisplatin}})k_k V_1 \\ \frac{dV_2}{dt} &= S(C_{\text{cisplatin}})k_k V_1 - k_k V_2 \\ \frac{dV_3}{dt} &= k_k V_2 - k_k V_3 \\ \frac{dV_4}{dt} &= k_k V_3 - k_k V_4\end{aligned}\quad (6)$$

Results: Drug exposure models

The parameter value for the cetuximab model should be $k_e = 0.017\text{h}^{-1}$, $k_a = 0.44\text{h}^{-1}$, $F = 1$, and $V = 94\text{mL} \cdot \text{kg}^{-1}$.

The parameter values for the cisplatin model should be $k_a = 42\text{h}^{-1}$, $k_{10} = 1.3\text{h}^{-1}$, $k_{12} = 3.3\text{h}^{-1}$, $k_{21} = 0.047\text{h}^{-1}$, $F = 1$, and $V_p = 377\text{mL} \cdot \text{kg}^{-1}$.

Table I

In the third column the between-subject variability values should be 10 and 33 (instead of 0.10 and 0.33)

In the second column the value of $\text{Cov}(k_g, V^0)$ should be changed to 0.017 (instead of 0.13).

Appendix 1

The first line should read: "Consider the unperturbed tumor model incorporating natural cell death, with main compartment V_1 and damage compartments V_2, \dots, V_n , described by the following system of differential equations"

Equation 36: The vectors should be

$$\begin{aligned}\mathbf{w}_{2,2} &= (0, 0, \dots, 0, 1, 0), \mathbf{w}_{2,3} = (0, \dots, 0, 1, 0, 0), \dots, \mathbf{w}_{2,n} \\ &= (0, 1, 0, \dots, 0)\end{aligned}\quad (36)$$

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-016-9991-1>.

¹Fraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden.

²Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.

³Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.

⁴Global Early Development-Quantitative Pharmacology and Drug Disposition, Quantitative Pharmacology, Merck, Darmstadt, Germany.

⁵Present Address: Pharmaceutical Research and Early Development, Hoffmann-Le Roche, Basel, Switzerland.

⁶Translation Innovation Platform Oncology, Merck, Darmstadt, Germany.

⁷Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.